These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18492463)

  • 1. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
    Wong ET; Brem S
    J Natl Compr Canc Netw; 2008 May; 6(5):515-22. PubMed ID: 18492463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapies for glioblastoma.
    Arrillaga-Romany I; Norden AD
    CNS Oncol; 2014; 3(5):349-58. PubMed ID: 25363007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
    Argyriou AA; Giannopoulou E; Kalofonos HP
    Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis in glioblastoma multiforme: navigating the maze.
    Linkous AG; Yazlovitskaya EM
    Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
    Wang N; Jain RK; Batchelor TT
    Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
    de Boüard S; Guillamo JS
    Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.
    Takano S
    Brain Tumor Pathol; 2012 Apr; 29(2):73-86. PubMed ID: 22218709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts.
    Lund EL; Bastholm L; Kristjansen PE
    Clin Cancer Res; 2000 Mar; 6(3):971-8. PubMed ID: 10741723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring therapeutic monoclonal antibodies in brain tumor.
    Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Beck A; Chinot O; Lafitte D
    MAbs; 2014; 6(6):1385-93. PubMed ID: 25484065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration.
    Bazan NG; Reid MM; Flores VAC; Gallo JE; Lewis W; Belayev L
    Cancer Metastasis Rev; 2021 Sep; 40(3):643-647. PubMed ID: 34519960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
    de Groot J; Reardon DA; Batchelor TT
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme.
    Gossmann A; Helbich TH; Kuriyama N; Ostrowitzki S; Roberts TP; Shames DM; van Bruggen N; Wendland MF; Israel MA; Brasch RC
    J Magn Reson Imaging; 2002 Mar; 15(3):233-40. PubMed ID: 11891967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
    Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
    Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
    Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
    J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.